Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 757-762

  Abrahamsen, B ^a,b   Grove, E L ^c   Vestergaard, P ^d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Drug safety; Epidemiology; Mortality; Osteoporosis; Strontium ranelate

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG USE; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; UNCONTROLLED HYPERTENSION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DENMARK; DRUG UTILIZATION; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DATABASES, FACTUAL; DENMARK; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; REGISTRIES; RISK FACTORS; THIOPHENES; TREATMENT OUTCOME;

EID: 84899050195     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2469-4     Document Type: Article

References (10)

1. EMA (2013) Recommendation to restrict the use of Protelos / Osseor (strontium ranelate). http://www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2013/04/WC500142507.pdf Accessed 15 June 2013
2. Osborne V, Layton D, Perrio M, Wilton L, Shakir SAW, Saad AW (2010) Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf Int J Med Toxicol Drug Experience 33(7):579-591
3. Ulger Z, Gurel EI, Halil M, Oozen G, Kalan I, Seringec N et al. (2012) Hemorheological changes with strontium ranelate treatment do not seem to be related to its claimed prothrombotic effects. Arch Gerontol Geriatr 54(1):218-221
4. Pazianas M, Clark EM, Eiken P a, Brixen K, Abrahamsen B (2012) Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications - cohort analysis using a national prescription database. Journal of bone andmineral research.Off J Am Soc Bone Miner Res 28(3):455-463
5. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY (2009) Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21(5):723-32. doi:10.1007/s00198-009-1097-5
6. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M (2003) The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56(2):124-130 (Pubitemid 36315938)
7. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T (2007) Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28(3):150-154 (Pubitemid 47344336)
8. Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients - a nationwide register-based open cohort study. Osteoporos Int. 24(1):245-52. doi:10.1007/s00198-012-2024-8
9. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95(3):1174-1181
10. Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS (2013) Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. JBMR 28(5):984-991